NCT06715670View on ClinicalTrials.gov

A Study to Investigate the Blood Concentrations of 4 Different Oral Doses of Zibotentan in Healthy Non-Asian and Japanese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 5, 2024

Primary Completion Date

February 19, 2025

Study Completion Date

February 19, 2025

Conditions
Liver Cirrhosis
Interventions
DRUG

Zibotentan

Participant will receive 4 different single doses of zibotentan on Day 1 of each treatment period orally.

Trial Locations (1)

91206

Research Site, Glendale

Sponsors

Lead Sponsor

AstraZeneca

Collaborators (1)

Parexel
All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

AstraZeneca

INDUSTRY